Chiltern earns five spots in PharmaTimes Clinical Researcher of the Year finals
LONDON and WILMINGTON, N.C., Jan. 27, 2015 /PRNewswire/ -- Chiltern, a leading global CRO, has earned five nominations in the PharmaTimes Clinical Researcher of the Year finals for the Project Manager, Clinical Research Associate (CRA) and New CRA categories.
"I have been involved with the Clinical Researcher of the Year competition for several years and I could not be more proud of our group this year, said Susan Romberg, Chiltern's Vice President of Global Clinical Development. Our nominees have put forth a tremendous effort to earn a chance to compete in the finals and they deserve recognition as some of brightest performers in our industry. Everyone at Chiltern is looking forward to a fun and competitive finals."
The PharmaTimes Clinical Researcher of the Year is a multi-stage competition designed to test the knowledge, competency and innovation toward finding the top performing clinical researchers globally. Finalists will have the opportunity to compete during a one-day challenge to be held at the Cary headquarters of the SAS Institute on 26th February with an awards ceremony to follow that evening. Finalists are selected by an executive committee of industry experts from small and large biopharmaceutical companies, site management groups, CROs, and other organizations involved in clinical research.
Chiltern nominees Erik Nicolai and Amy Sinclair will compete in the Project Manager category; Candie McDevitt and Laura Goucher, CRA category; and Jessica Norton, New CRA category.
Chiltern COO Aize Smink added, "This is a recognition of Chiltern's dedication to hiring and developing the best clinical research staff in the world, and a real testament to the quality and efforts of our people. We would like to thank everyone who participated this year with a special congratulations to all finalists. It is the spirit of competition that brings out the best in us all."
About Chiltern:
Chiltern is a leading global CRO that listens to client needs in order to customize solutions for the Biopharma industry. With 33 years in service, Chiltern delivers from three specialized business units: Chiltern Biopharma, with deep therapeutic expertise for respiratory, anti-infectives / vaccines, ophthalmology, dermatology and other specialty areas; Chiltern Oncology, led by physicians, scientists and clinicians to uniquely manage all phases of hematologic and oncologic clinical drug development; and Chiltern Source, a world leader in tailored relationships for FSP, resourcing and staffing solutions. Chiltern's 2,200 engaged professionals work across 45 countries to deliver flexible, responsive solutions that are "Designed Around You".
Further information is available at: http://www.chiltern.com.
For more information contact:
Nicholas Spittal
Sr. Director, Global Commercial Affairs
Chiltern International Inc.
4000 Centregreen Way, Suite 300
Cary, NC 27513
USA
Tel: +1 (919) 462 8867
Email: [email protected]
SOURCE Chiltern
Share this article